India’s Nasal COVID Vaccine To Be Available From January

New Delhi: According to Bharat Biotech, the public will be able to purchase the Covid-19 nasal vaccination, iNCOVACC, starting in the fourth week of January. The vaccine would cost 325 rupees for governments and 800 rupees for private markets, the Hyderabad-based biotechnology company said.

The INCOVACC from Bharat Biotech is the first intranasal Covid vaccine in the world to be approved for both the primary 2-dose schedule and a heterologous booster dose. The nasal vaccine will be administered as a booster dose for those over 18. iNCOVACC was developed by Bharat Biotech in collaboration with Washington University in the United States.

You might also like

Comments are closed.